| Autor: |
Malfait AM; Rush University Medical School, Department of Medicine, Division of Rheumatology, Chicago IL, USA. anne-marie_malfait@rush.edu., Tortorella MD; Guangzhou Institutes of Biomedical Health, Chinese Academy of Sciences, Guangzhou, China. |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2019 Sep-Oct; Vol. 37 Suppl 120 (5), pp. 130-134. Date of Electronic Publication: 2019 Oct 15. |
| Abstrakt: |
From the time of their discovery in 1999, the aggrecanases, and ADAMTS-5 in particular, have been heavily investigated as targets for disease-modifying osteoarthritis drug (DMOAD) development. Here, we provide a brief narrative review of the discovery efforts to target these enzymes, and how this led to the current ongoing programmes that hold promise for the future. We discuss a comparison of inhibition of collagen breakdown versus inhibition of aggrecan breakdown. We then summarise existing programmes that target ADAMTS-5, including small molecule inhibitors, monoclonal neutralising antibodies and nanobodies, and gene editing technologies. We also briefly discuss the potential analgesic effects this strategy may offer in addition to its joint-protective effects. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
